Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy

Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase

“…Aldose reductase is a key rate-limiting enzyme of the polyol pathway, and controlling its activity can lower blood glucose and thus alleviate diabetic complications [36,[58][59][60]. However, recent research evidence suggests that aldose reductase is an outstanding facilitator to regulate inflammatory signals [37,61]. Accordingly, preventing inflammatory complications may be a potential use of aldose reductase inhibition.…”

Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase

“…Aldose reductase is a key rate-limiting enzyme of the polyol pathway, and controlling its activity can lower blood glucose and thus alleviate diabetic complications [36,[58][59][60]. However, recent research evidence suggests that aldose reductase is an outstanding facilitator to regulate inflammatory signals [37,61]. Accordingly, preventing inflammatory complications may be a potential use of aldose reductase inhibition.…”

Wound, pressure ulcer, and burn guidelines – 3: Guidelines for the diagnosis and treatment of diabetic ulcers and gangrene, second edition

“…There is a RCT 253 and a meta‐analysis 254 on mexiletine hydrochloride, and so the evidence level is I and the recommendation level is 1A. For diabetic neuropathy, there are two systematic reviews on epalrestat 255,256 and so the evidence level is I, but no significant difference in treatment effect was seen when compared to placebos. In addition, there is a meta‐analysis 257 with an evidence level of I, but the effectiveness determination differed depending on the parameters evaluated, so the recommendation level was set at 2A. Diabetic neuropathy is the most common complication. The primary type is diabetic polyneuropathy and includes polyneuropathy of the sensory and autonomic nerves and painful diabetic neuropathy.…”

“…Their administration is considered for intractable cases. It has been suggested that multiple factors such as metabolic disorders, decreased blood flow, abnormal nerve regeneration, and similar conditions are involved in the origin of sensory disturbances in polyneuropathy. Among these, polyol metabolism disorders are the most important causative factors; aldose reductase is activated in hyperglycemic states, promoting polyol metabolism pathways. There are two systematic reviews that provide a comprehensive evaluation of aldose reductase inhibitors (ARIs) indicating that they did not produce a significantly different therapeutic effect compared to placebos in polyneuropathy patients 256,257 . In addition, there is a meta‐analysis stating that although ARIs improve motor nerve conduction velocity (NCV) compared to a control group, they do not produce a significant effect in other parameters and it is difficult to evaluate in a short‐term study 258 …”

“…• For diabetic neuropathy, there are two systematic reviews on epalrestat 255,256 and so the evidence level is I, but no significant difference in treatment effect was seen when compared to placebos. In addition, there is a meta-analysis 257 with an evidence level of I, but the effectiveness determination differed depending on the parameters evaluated, so the recommendation level was set at 2A.…”

“…• There are two systematic reviews that provide a comprehensive evaluation of aldose reductase inhibitors (ARIs) indicating that they did not produce a significantly different therapeutic effect compared to placebos in polyneuropathy patients. 256,257 In addition, there is a meta-analysis stating that although ARIs improve motor nerve conduction velocity (NCV) compared to a control group, they do not produce a significant effect in other parameters and it is difficult to evaluate in a short-term study. 258 • Epalrestat is approved in Japan and is the subject of the greatest number of reports.…”

Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase

“…Aldose reductase is a key rate-limiting enzyme of the polyol pathway, and controlling its activity can lower blood glucose and thus alleviate diabetic complications [36,[58][59][60]. However, recent research evidence suggests that aldose reductase is an outstanding facilitator to regulate inflammatory signals [37,61]. Accordingly, preventing inflammatory complications may be a potential use of aldose reductase inhibition.…”

Wound, pressure ulcer, and burn guidelines – 3: Guidelines for the diagnosis and treatment of diabetic ulcers and gangrene, second edition

“…There is a RCT 253 and a meta‐analysis 254 on mexiletine hydrochloride, and so the evidence level is I and the recommendation level is 1A. For diabetic neuropathy, there are two systematic reviews on epalrestat 255,256 and so the evidence level is I, but no significant difference in treatment effect was seen when compared to placebos. In addition, there is a meta‐analysis 257 with an evidence level of I, but the effectiveness determination differed depending on the parameters evaluated, so the recommendation level was set at 2A. Diabetic neuropathy is the most common complication. The primary type is diabetic polyneuropathy and includes polyneuropathy of the sensory and autonomic nerves and painful diabetic neuropathy.…”

“…Their administration is considered for intractable cases. It has been suggested that multiple factors such as metabolic disorders, decreased blood flow, abnormal nerve regeneration, and similar conditions are involved in the origin of sensory disturbances in polyneuropathy. Among these, polyol metabolism disorders are the most important causative factors; aldose reductase is activated in hyperglycemic states, promoting polyol metabolism pathways. There are two systematic reviews that provide a comprehensive evaluation of aldose reductase inhibitors (ARIs) indicating that they did not produce a significantly different therapeutic effect compared to placebos in polyneuropathy patients 256,257 . In addition, there is a meta‐analysis stating that although ARIs improve motor nerve conduction velocity (NCV) compared to a control group, they do not produce a significant effect in other parameters and it is difficult to evaluate in a short‐term study 258 …”

“…• For diabetic neuropathy, there are two systematic reviews on epalrestat 255,256 and so the evidence level is I, but no significant difference in treatment effect was seen when compared to placebos. In addition, there is a meta-analysis 257 with an evidence level of I, but the effectiveness determination differed depending on the parameters evaluated, so the recommendation level was set at 2A.…”

“…• There are two systematic reviews that provide a comprehensive evaluation of aldose reductase inhibitors (ARIs) indicating that they did not produce a significantly different therapeutic effect compared to placebos in polyneuropathy patients. 256,257 In addition, there is a meta-analysis stating that although ARIs improve motor nerve conduction velocity (NCV) compared to a control group, they do not produce a significant effect in other parameters and it is difficult to evaluate in a short-term study. 258 • Epalrestat is approved in Japan and is the subject of the greatest number of reports.…”

Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase

“…Aldose reductase is a key rate-limiting enzyme of the polyol pathway, and controlling its activity can lower blood glucose and thus alleviate diabetic complications [36,[58][59][60]. However, recent research evidence suggests that aldose reductase is an outstanding facilitator to regulate inflammatory signals [37,61]. Accordingly, preventing inflammatory complications may be a potential use of aldose reductase inhibition.…”

Wound, pressure ulcer, and burn guidelines – 3: Guidelines for the diagnosis and treatment of diabetic ulcers and gangrene, second edition

“…There is a RCT 253 and a meta‐analysis 254 on mexiletine hydrochloride, and so the evidence level is I and the recommendation level is 1A. For diabetic neuropathy, there are two systematic reviews on epalrestat 255,256 and so the evidence level is I, but no significant difference in treatment effect was seen when compared to placebos. In addition, there is a meta‐analysis 257 with an evidence level of I, but the effectiveness determination differed depending on the parameters evaluated, so the recommendation level was set at 2A. Diabetic neuropathy is the most common complication. The primary type is diabetic polyneuropathy and includes polyneuropathy of the sensory and autonomic nerves and painful diabetic neuropathy.…”

“…Their administration is considered for intractable cases. It has been suggested that multiple factors such as metabolic disorders, decreased blood flow, abnormal nerve regeneration, and similar conditions are involved in the origin of sensory disturbances in polyneuropathy. Among these, polyol metabolism disorders are the most important causative factors; aldose reductase is activated in hyperglycemic states, promoting polyol metabolism pathways. There are two systematic reviews that provide a comprehensive evaluation of aldose reductase inhibitors (ARIs) indicating that they did not produce a significantly different therapeutic effect compared to placebos in polyneuropathy patients 256,257 . In addition, there is a meta‐analysis stating that although ARIs improve motor nerve conduction velocity (NCV) compared to a control group, they do not produce a significant effect in other parameters and it is difficult to evaluate in a short‐term study 258 …”

“…• For diabetic neuropathy, there are two systematic reviews on epalrestat 255,256 and so the evidence level is I, but no significant difference in treatment effect was seen when compared to placebos. In addition, there is a meta-analysis 257 with an evidence level of I, but the effectiveness determination differed depending on the parameters evaluated, so the recommendation level was set at 2A.…”

“…• There are two systematic reviews that provide a comprehensive evaluation of aldose reductase inhibitors (ARIs) indicating that they did not produce a significantly different therapeutic effect compared to placebos in polyneuropathy patients. 256,257 In addition, there is a meta-analysis stating that although ARIs improve motor nerve conduction velocity (NCV) compared to a control group, they do not produce a significant effect in other parameters and it is difficult to evaluate in a short-term study. 258 • Epalrestat is approved in Japan and is the subject of the greatest number of reports.…”